New Delhi: Refusing to move an interim order on permission granted by the Drugs Controller General of India (DCGI) to Bharat Biotech for conducting section two and three medical trial of covaxin on the 2-18 age group, the Delhi High Court on Wednesday issued a discover to the Centre and Bharat Biotech.
Seeking the stand of the Centre and Bharat Biotech by July 15 on the petition, a bench of Chief Justice DN Patel and Justice Jyoti Singh declined to move any interim order staying the permission granted earlier on May 12 for medical trials as sought by petitioner Sanjeev Kumar.
ALSO READ |Â ‘Delhi CM Doesn’t Speak For India’: Centre Responds As Singapore Objects To Kejriwal’s Covid Strain Remarks
This got here as a PIL to put aside the permission granted by the DCGI was heard by the Delhi High Court.
The vaccine will likely be given by intramuscular route in two doses at day 0 and day 28 within the trial to be performed on 525 wholesome volunteers.
Earlier on Tuesday, Niti Aayog Member (Health) Dr V.Okay. Paul had stated covaxin has been authorised by the DCGI for section two and three medical trials within the age group of two to 18 years, including the trials will start within the subsequent 10 to 12 days.
